

Junshi Bioscience and Hikma expand cancer treatment to Middle East and North Africa

28 December 2022 | News

Sign exclusive licensing agreement for cancer treatment drug toripalimab for the Middle East and North Africa region



UK-headquartered Hikma Pharmaceuticals has announced a new exclusive licensing and commercialisation agreement with Chinese firm Junshi Biosciences for toripalimab in the Middle East and North Africa (MENA).

Under the terms of the agreement, Hikma has an exclusive license to develop and commercialise toripalimab injection in all its MENA markets. In addition, Hikma has the right of first negotiation for the future commercialisation of three under-development drugs in MENA.

Toripalimab is an innovative anti-PD-1 monoclonal antibody approved for marketing in China for six indications to date. Over thirty toripalimab clinical studies covering more than fifteen indications have been conducted globally, including in China, the United States, Southeast Asia, and Europe.

Ongoing or completed pivotal clinical studies evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin, among others.

As part of this collaboration, Hikma has acquired rights to commercialise any combination product that comprises any therapeutically active pharmaceutical agent co-formulated or co-packaged with toripalimab. Hikma has also acquired exclusive rights of first negotiation to three of Junshi Biosciences' novel oncology molecules.